Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: Good virological response but high rate of toxicity

Barbara Castelnuovo, Laurence John, Fred Lutwama, Allan Ronald, Lisa A. Spacek, Michael Bates, Moses R. Kamya, Robert Colebunders

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. To evaluate the safety and virological response to lopinavir/ritonavir containing second-line therapy after failing a first line nonnucleoside reverse transcriptase inhibitor (NNRTI) based regimen. Design. Prospective 36 months cohort study of patients switched to zidovudine/stavudine plus didanosine plus lopinavir/ritonavir capsules as second-line regimen. Methodology. Structured interview, medical examination, and laboratory assessment performed every 6 months. Results. We enrolled 40 patients; 1 died and 3 were lost to follow-up. Median CD4+ count at baseline was 108 cell/μL, median log viral load was 4.8 copies/mL. Sixteen (40%) patients had baseline genotypic resistant test, 14 (87%) had lamivudine resistance mutations, and all had NNRTIs resistance mutations. At month 36, 82% of the patients achieved viral suppression (

Original languageEnglish (US)
Pages (from-to)52-59
Number of pages8
JournalJournal of the International Association of Physicians in AIDS Care
Volume8
Issue number1
DOIs
StatePublished - Jan 2009

Keywords

  • resource-limited settings
  • second-line antiretroviral therapy
  • virological response

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology
  • Dermatology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: Good virological response but high rate of toxicity'. Together they form a unique fingerprint.

Cite this